Key Points
- CEO Martine Rothblatt sold 9,500 UTHR shares on April 10 at an average price of $569.28 (≈$5.41M), trimming her stake by 19% to 40,513 shares valued at about $23.06M.
- United Therapeutics posted a strong quarter—EPS $7.70 beat estimates and revenue rose 7.4% YoY—and analysts remain largely positive, with a consensus "Moderate Buy" and an average price target of $601.50 after several target increases.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction on Friday, April 10th. The stock was sold at an average price of $569.28, for a total transaction of $5,408,160.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares of the company's stock, valued at $23,063,240.64. The trade was a 19.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
United Therapeutics Trading Up 1.0%
NASDAQ:UTHR opened at $577.63 on Tuesday. The firm's fifty day simple moving average is $518.73 and its 200 day simple moving average is $486.05. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $607.89. The firm has a market capitalization of $25.32 billion, a price-to-earnings ratio of 20.70, a PEG ratio of 1.65 and a beta of 0.75.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. During the same period in the prior year, the firm earned $6.19 EPS. The firm's quarterly revenue was up 7.4% compared to the same quarter last year. On average, analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.
Analyst Ratings Changes
UTHR has been the topic of several analyst reports. Royal Bank Of Canada raised their target price on United Therapeutics from $587.00 to $643.00 and gave the company an "outperform" rating in a report on Thursday, February 26th. Wells Fargo & Company upped their price target on United Therapeutics from $486.00 to $575.00 and gave the stock an "equal weight" rating in a report on Tuesday, March 31st. Oppenheimer lifted their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a research note on Thursday, February 26th. HC Wainwright boosted their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a "buy" rating in a research report on Tuesday, March 31st. Finally, Jefferies Financial Group restated a "buy" rating on shares of United Therapeutics in a research note on Monday, March 2nd. Ten equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, United Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $601.50.
Get Our Latest Stock Report on UTHR
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the business. AE Wealth Management LLC increased its stake in shares of United Therapeutics by 396.3% in the third quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company's stock worth $1,798,000 after buying an additional 3,424 shares during the last quarter. Great Lakes Advisors LLC raised its holdings in United Therapeutics by 194.7% in the third quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company's stock valued at $1,888,000 after acquiring an additional 2,975 shares in the last quarter. Optimize Financial Inc bought a new position in United Therapeutics during the 3rd quarter valued at $444,000. Simplify Asset Management Inc. acquired a new position in United Therapeutics during the 3rd quarter worth $8,351,000. Finally, Osaic Holdings Inc. grew its holdings in United Therapeutics by 271.0% during the 2nd quarter. Osaic Holdings Inc. now owns 46,082 shares of the biotechnology company's stock worth $14,027,000 after acquiring an additional 33,662 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
